LCAR-C182A is a CAR-T cell therapy given after lymphodepleting fludarabine and cyclophosphamide. It is studied in gastric cancer and pancreatic ductal adenocarcinoma.
Summary written with AI from the sources listed at the end of this page.
At a glance
Drug type
Cell therapy (CAR-T)
Targets
Claudin 18.2 (CLDN18) (antigen)
Mechanism
Kills target cells, directed at Claudin 18.2 (CLDN18)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.